Clinical trial
Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With…
NCT00356096 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00356096 |
|---|---|
| Title | Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances |
| Official title | A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome, Depression |
| Intervention type | Drug |
| Interventions | pramipexole |
| Enrollment | 404 |
| Start date | Jul 1, 2006 |
| Primary completion | Jun 1, 2007 |
| First posted | Jul 25, 2006 |
| Last update posted | May 21, 2012 |
| Countries | Finland, France, Germany, Ireland, Italy, South Korea, Spain, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: